title: Curative one-shot systemic virotherapy in murine myeloma.
abstract: Current therapy for multiple myeloma is complex and prolonged. Antimyeloma drugs are combined in induction, consolidation and/or maintenance protocols to destroy bulky disease, then suppress or eradicate residual disease. Oncolytic viruses have the potential to mediate both tumor debulking and residual disease elimination, but this curative paradigm remains unproven. Here, we engineered an oncolytic vesicular stomatitis virus to minimize its neurotoxicity, enhance induction of antimyeloma immunity and facilitate noninvasive monitoring of its intratumoral spread. Using high-resolution imaging, autoradiography and immunohistochemistry, we demonstrate that the intravenously administered virus extravasates from tumor blood vessels in immunocompetent myeloma-bearing mice, nucleating multiple intratumoral infectious centers that expand rapidly and necrose at their centers, ultimately coalescing to cause extensive tumor destruction. This oncolytic tumor debulking phase lasts only for 72 h after virus administration, and is completed before antiviral antibodies become detectable in the bloodstream. Antimyeloma T cells, cross-primed as the virus-infected cells provoke an antiviral immune response, then eliminate residual uninfected myeloma cells. The study establishes a curative oncolytic paradigm for multiple myeloma where direct tumor debulking and immune eradication of minimal disease are mediated by a single intravenous dose of a single therapeutic agent. Clinical translation is underway.
authors.affiliation: Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
authors.forename: S
authors.initials: S
authors.lastname: Naik
authors.forename: R
authors.initials: R
authors.lastname: Nace
authors.forename: M J
authors.initials: MJ
authors.lastname: Federspiel
authors.forename: G N
authors.initials: GN
authors.lastname: Barber
authors.forename: K-W
authors.initials: KW
authors.lastname: Peng
authors.forename: S J
authors.initials: SJ
authors.lastname: Russell
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D006224:Cricetinae; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D016899:Interferon-beta / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009101:Multiple Myeloma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics; D027981:Symporters / Q000235:genetics / Q000378:metabolism; D014185:Transplantation, Isogeneic; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics; D000099209:Sodium-Iodide Symporters
chemical_list: D016899:Interferon-beta; D027981:Symporters; D000099209:Sodium-Iodide Symporters